Detect these cancers at their earliest stages, ultimately improving outcomes
For decades, head and neck cancers driven by the human papillomavirus have arrived without warning, diagnosed only after tumors had already taken root and spread. Researchers at Mass General Brigham have now developed a blood test called HPV-DeepSeek that can detect these cancers up to ten years before a single symptom appears, using whole genome sequencing and machine learning to find traces of tumor DNA circulating in the bloodstream. In a disease where late diagnosis has long meant aggressive, life-altering treatment, this tool represents a quiet but profound shift in what medicine can offer — the possibility of knowing, and acting, long before the body speaks.
- HPV drives seven in ten head and neck cancers in the US, yet unlike cervical cancer, no routine screening test has ever existed to catch it early — leaving patients to discover their illness only when tumors are already large and spreading.
- The HPV-DeepSeek liquid biopsy achieved 96% accuracy in detecting cancer cases, including blood samples drawn nearly a decade before any diagnosis, a result that redraws the boundary of what early detection can mean.
- Without early intervention, patients face treatments so aggressive their side effects — pain, difficulty swallowing, lasting physical damage — become a second burden carried for the rest of their lives.
- Validation studies using hundreds of samples from the PLCO cancer screening trial are now underway, the critical next step before this test could reach the clinics where asymptomatic patients most need it.
In the United States, human papillomavirus causes roughly seven out of ten head and neck cancers, and that proportion keeps rising. Unlike cervical cancer, there is no routine screening method to catch HPV-linked head and neck tumors before they make themselves known. By the time most patients receive a diagnosis, the disease has already spread, and the treatments required leave permanent side effects.
Researchers at Mass General Brigham set out to change that. Their test, HPV-DeepSeek, is a liquid biopsy that searches blood for tiny fragments of HPV DNA shed by tumors into the bloodstream. In earlier work, it reached 99% accuracy at the moment of clinical diagnosis. The new question was whether it could work years sooner.
To find out, the team analyzed 56 blood samples from a biobank — 28 from people who would later develop HPV-associated head and neck cancer, and 28 from healthy controls. The test detected tumor DNA in 22 of the 28 patient samples while returning no false positives among the controls. The earliest detection came from a sample drawn nearly eight years before diagnosis.
With machine learning applied to sharpen its precision, HPV-DeepSeek correctly identified 27 of the 28 cancer cases, including samples collected up to ten years before any symptoms appeared. Dr. Daniel L. Faden, the surgical oncologist leading the research, noted that catching these cancers at their earliest stages could spare patients from the severe, lifelong consequences of late-stage treatment.
The findings were published in The Journal of the National Cancer Institute. A larger, blinded validation study is now underway using hundreds of samples from the PLCO cancer screening trial, funded by the National Institutes of Health. If those results confirm what has already been seen, HPV-DeepSeek could eventually offer asymptomatic people something that has never existed before: a chance to know, and to act, years ahead of the disease.
In the United States, human papillomavirus is responsible for roughly seven out of every ten cases of head and neck cancer, a proportion that climbs higher each year. Unlike cervical cancer, which can be caught through routine screening, there is currently no test that can identify HPV-linked head and neck cancers before symptoms arrive. Most patients learn they have the disease only after tumors have grown to billions of cells, often spreading to nearby lymph nodes and producing unmistakable signs. By then, treatment becomes aggressive and the side effects linger for life.
Researchers at Mass General Brigham have developed a test that changes this equation. Called HPV-DeepSeek, it is a liquid biopsy—a blood test—capable of spotting these cancers up to a decade before a person feels sick. The test uses whole genome sequencing to hunt for tiny fragments of HPV DNA that have broken free from a tumor and entered the bloodstream. In earlier work, the team showed the test could achieve 99 percent accuracy when identifying cancer at the moment of clinical diagnosis, outperforming every existing diagnostic method.
To see whether HPV-DeepSeek could work years before symptoms emerged, researchers examined 56 blood samples from the Mass General Brigham biobank. Twenty-eight came from people who later developed HPV-associated head and neck cancer. Twenty-eight came from healthy individuals serving as controls. The test detected tumor DNA in 22 of the 28 patient samples while returning negative results for all 28 control samples, demonstrating its precision. The earliest positive result came from a blood sample collected 7.8 years before diagnosis.
Using machine learning to sharpen the test's power, the team improved its performance further. It now identified 27 of the 28 cancer cases accurately, including samples drawn as much as ten years before diagnosis. Dr. Daniel L. Faden, the surgical oncologist leading the research at Mass Eye and Ear, emphasized the stakes in a statement: when patients arrive at clinics with cancer symptoms, they face treatments that cause severe and permanent side effects. A tool like HPV-DeepSeek, he said, could allow doctors to catch these cancers at their earliest stages, ultimately improving outcomes and quality of life.
The findings were published in The Journal of the National Cancer Institute, supported by British federal funding. But the work is far from finished. The research team is now validating these results in a second, blinded study financed by the National Institutes of Health. This larger trial will use hundreds of blood samples collected as part of the PLCO cancer screening study at the British National Cancer Institute. If those results hold, HPV-DeepSeek could move toward clinical use, offering asymptomatic people a way to know their cancer risk years before the disease announces itself.
Notable Quotes
When patients arrive at clinics with cancer symptoms, they face treatments that cause severe and permanent side effects. A tool like HPV-DeepSeek could allow doctors to catch these cancers at their earliest stages, ultimately improving outcomes and quality of life.— Dr. Daniel L. Faden, surgical oncologist at Mass General Brigham
The Hearth Conversation Another angle on the story
Why does HPV-linked head and neck cancer stay hidden for so long before symptoms show up?
The virus integrates into cells and the tumor grows silently. By the time someone feels pain or notices a lump, the cancer has already spread to lymph nodes. That's when it becomes obvious and dangerous.
And the current screening tests just don't work for this?
Exactly. We have excellent screening for cervical cancer because we can sample the cervix directly. But head and neck cancers are harder to reach, and there's been no blood test until now that could catch them early.
So this test is looking for HPV DNA in the blood. How does that work?
When a tumor sheds cells, fragments of its DNA leak into the bloodstream. HPV-DeepSeek sequences the entire genome and hunts for those specific viral fragments. It's like finding a needle in a haystack, but the machine learning helps identify which needles matter.
The study found it could detect cancer ten years early. That seems almost too good to be true.
The earliest detection in this study was 7.8 years. With machine learning, they pushed it to ten. But they're being careful—they're running a much larger validation study now before claiming this is ready for clinics.
What changes if someone gets diagnosed ten years early?
Everything. Instead of aggressive surgery and radiation that cause permanent damage, you might catch it when it's still treatable with less toxic approaches. You get your life back instead of living with lifelong side effects.
When will this actually be available to patients?
Not yet. The validation study is underway. If it works in hundreds more samples, then you'd see clinical trials and eventually, if approved, it becomes part of routine screening for high-risk people.